Physician profile
Pramit Bhasin
NPI 1447221478
$9,636.35
in general payments reported to CMS, 2019-2025
36 companies · $802 in 2025
The $802 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $583 · 2020: $19.52 · 2021: $2,314 · 2022: $2,477 · 2023: $190 · 2024: $3,251 · 2025: $802.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,273 · Travel and Lodging: $1,970.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,272.96 |
| Travel and Lodging | $1,969.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $3,346.12 | 2021-2025 | Linq II |
| E.R. Squibb & Sons, L.L.C. | $1,575.00 | 2022 | |
| Alexion Pharmaceuticals, INC. | $817.53 | 2021-2025 | Ultomiris |
| Celgene Corporation | $644.01 | 2021-2022 | |
| Lundbeck LLC | $379.25 | 2019-2025 | Vyepti |
| Teva Pharmaceuticals USA, INC. | $369.98 | 2021-2022 | |
| Livanova USA, INC. | $359.93 | 2021-2022 | |
| Novo Nordisk INC | $221.42 | 2021-2023 | Wegovy |
| Biohaven Pharmaceuticals, INC. | $213.01 | 2021 | |
| Novartis Pharmaceuticals Corporation | $208.54 | 2021-2025 | |
| Abbvie INC. | $189.80 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $145.44 | 2022 | |
| Taiho Oncology, INC. | $124.82 | 2021 | |
| Hyperfine Operations, INC. | $122.85 | 2025 | Swoop |
| Lilly USA, LLC | $114.40 | 2019 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $101.26 | 2019 | |
| Amgen INC. | $91.63 | 2019 | |
| Biogen, INC. | $90.43 | 2019-2024 | Vumerity, Tysabri |
| Allergan, INC. | $86.47 | 2021 | |
| Acadia Pharmaceuticals INC | $83.09 | 2019 | |
| Mallinckrodt Enterprises LLC | $42.04 | 2019 | |
| Acorda Therapeutics, INC | $41.89 | 2023 | Inbrija |
| Vanda Pharmaceuticals INC. | $28.75 | 2024 | Ponvory |
| Merz Pharmaceuticals, LLC | $25.02 | 2025 | Xeomin |
| Sk Life Science, INC. | $23.23 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $20.99 | 2019 | |
| Argenx US, INC. | $19.25 | 2025 | Vyvgart Hytrulo |
| Pfizer INC. | $19.18 | 2025 | |
| Grifols USA, LLC | $18.91 | 2025 | Gamunex-C |
| Ucb, INC. | $18.67 | 2025 | Nayzilam |
| Emd Serono, INC. | $17.42 | 2019 | |
| Ge Healthcare | $16.85 | 2019 | |
| Amneal Pharmaceuticals LLC | $15.50 | 2024 | Ongentys |
| Arbor Pharmaceuticals, INC. | $15.06 | 2019 | |
| Neurelis, INC. | $14.66 | 2025 | Valtoco |
| Avanir Pharmaceuticals, INC. | $13.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pramit Bhasin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.